You do not have permission to access this chart.
Please Sign Up or Login
News for GW Pharmaceuticals plc (GWPH)
58 minutes ago |

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.




Drug Manufacturers—General




GW Pharmaceuticals plc Sovereign House Vision Park Chivers Way Histon Cambridge CB24 9BZ United Kingdom



44 1223 266 800

Leave a comment

Your email address will not be published. Required fields are marked *